正海生物1月6日获融资买入1134.67万元，融资余额1.31亿元

Group 1 - The core viewpoint of the news is that Zhenghai Biological has experienced a decline in both revenue and net profit, indicating potential challenges in its financial performance [2] - As of January 6, Zhenghai Biological's stock price decreased by 0.57%, with a trading volume of 72.16 million yuan, and a net financing buy of -2.11 million yuan [1] - The company has a total financing and securities balance of 132 million yuan, with the financing balance accounting for 3.48% of its market capitalization, which is below the 30% percentile level over the past year [1] Group 2 - For the period from January to September 2025, Zhenghai Biological reported an operating income of 276 million yuan, a year-on-year decrease of 5.36%, and a net profit attributable to shareholders of 67.4 million yuan, down 46.10% year-on-year [2] - The number of shareholders as of September 30 is 15,900, a decrease of 5.57% from the previous period, while the average circulating shares per person increased by 5.90% to 11,336 shares [2] - The company has distributed a total of 617 million yuan in dividends since its A-share listing, with 334 million yuan distributed over the past three years [2]